Physician profile
Michael E Fanelli
NPI 1770106965
$4,004.12
in general payments reported to CMS, 2019-2025
21 companies · $894 in 2025
The $894 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $343 · 2022: $704 · 2023: $1,010 · 2024: $1,053 · 2025: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,957.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,169.30 | 2021-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $1,116.54 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $457.76 | 2021-2025 | Pifeltro, Delstrigo, Capvaxive |
| Janssen Products, LP | $198.95 | 2021 | |
| Novo Nordisk INC | $188.41 | 2022-2025 | Wegovy |
| Abbvie INC. | $159.02 | 2024-2025 | |
| Janssen Biotech, INC. | $147.73 | 2021-2023 | Symtuza |
| Amgen INC. | $82.62 | 2025 | Repatha, Otezla |
| Theratechnologies INC. | $69.60 | 2023-2025 | Egrifta, Trogarzo |
| Antares Pharma, INC. | $67.04 | 2022-2023 | Xyosted, Nocdurna, Tlando |
| Glaxosmithkline, LLC. | $49.01 | 2023-2025 | Bexsero, Pediarix, Shingrix |
| Lilly USA, LLC | $48.07 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Napo Pharmaceuticals INC | $42.24 | 2024-2025 | Mytesi |
| Dynavax Technologies Corporation | $41.06 | 2022-2023 | Heplisav-B |
| Takeda Pharmaceuticals U.S.A., INC. | $35.11 | 2022-2023 | Trintellix |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $28.48 | 2022 | |
| Inspire Medical Systems, INC. | $25.00 | 2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $21.75 | 2025 | Rexulti |
| Alkermes, INC. | $21.44 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.10 | 2023 | Austedo Xr |
| Pfizer INC. | $16.89 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Fanelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.